Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1773-1780

  Kuhn, D M ^a   George, T ^a   Chandra, J ^a   Mukherjee, P K ^a   Ghannoum, M A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CHLORHEXIDINE; ECHINOCANDIN; ELASTOMER; FLUCONAZOLE; MICAFUNGIN; NYSTATIN; RAVUCONAZOLE; SILICONE; TERBINAFINE; TETRAZOLIUM; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; BIOMASS; BIOPROSTHESIS; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CELL STRUCTURE; CONFOCAL LASER MICROSCOPY; DRUG EFFECT; DRUG EFFICACY; DRY WEIGHT; FUNGUS CULTURE; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; BIOFILMS; CANDIDA; CULTURE MEDIA; DRUG RESISTANCE, MICROBIAL; FUNGAL PROTEINS; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; PEPTIDES; PEPTIDES, CYCLIC; POLYENES; PROSTHESIS-RELATED INFECTIONS; TRIAZOLES;

EID: 0036096359     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1773-1780.2002     Document Type: Article

References (58)

1. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
2. Predictors of adverse outcome in cancer patients with candidemia
3. Current and future antifungal therapy: New targets for antifungal agents
4. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis
5. Candida biofilms and their susceptibility to antifungal agents
6. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents
7. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
8. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species
9. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats
10. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
11. Use of antibiotic locks to treat colonized central venous catheters
12. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance
13. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro
14. Clinical and laboratory analyses of cytospin-prepared Gram stains for recovery and diagnosis of bacteria from sterile body fluids
15. Bacterial biofilms: A common cause of persistent infections
16. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
17. Microbial biofilms: From ecology to molecular genetics
18. Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B
19. Biofilm formation by Candida species on the surface of catheter materials in vitro
20. Resistance of Candida albicans biofilms to antifungal agents in vitro
21. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H -tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents
22. The biofilm glycocalyx as a resistance factor
23. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study
24. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations
25. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: Trends in etiology in 310 episodes
26. Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution
27. Surface-induced and biofilm-induced changes in gene expression
28. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces
29. Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies
30. Riddle of biofilm resistance
31. Mechanisms of biofilm resistance to antimicrobial agents
32. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida spp
33. Guidelines for the management of intravascular catheter-related infections
34. Therapeutic approaches in patients with candidemia: Evaluation in a multicenter prospective observational study
35. Risk factors for death in patients with candidemia
36. Biofilm formation as microbial development
37. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
38. Pattern of growth and respiratory activity of Saccharomyces cerevisiae (baker's yeast) cells growing entrapped in an insolubilized gelatin gel
39. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
40. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of candida species
41. Detection of amphotericin B-resistant Candida isolates in a brothbased system
42. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
43. Development of interpretive breakpoints for anti-fungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
44. Antifungal susceptibility testing: Practical aspects and current challenges
45. Practice guidelines for the treatment of candidiasis
46. Risk factors for candidemia in neonatal intensive care unit patients
47. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study
48. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
49. Characterization of phenotypic changes in Pseudomonas putida in response to surface-associated growth
50. Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: A simple method
51. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials
52. The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycoside and beta-lactam antibiotics
53. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans
54. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole- susceptible and -resistant Candida species
55. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers
56. Gene expression in Pseudomonas aeruginosa biofilms